Focused Ultrasound Foundation Sees Cancer, Alzheimer's Advances by 2029
Global clinical trials, including those led by researchers in Hong Kong, are expected to deliver significant progress in treating glioblastoma and pancreatic cancer within three years, according to the US-based Focused Ultrasound Foundation.
New Treatments for Difficult Cancers
Focused ultrasound technology is showing promise for conditions that are challenging to treat, according to Dr Neal Kassell, founder and chairman of the US-based Focused Ultrasound Foundation. This includes glioblastoma, an aggressive form of brain cancer, and pancreatic cancer. Researchers in Hong Kong and other global centres are currently conducting clinical trials. These studies aim to develop more effective treatments for these tumours using precisely targeted sound waves.
Three-Year Outlook for Advances
Dr Kassell estimates that important advances from the clinical trials for glioblastoma and pancreatic cancer could emerge in about three years. This projection points to potential breakthroughs in treatment options by 2029. Additionally, Alzheimer's disease is identified as another significant application for focused ultrasound technology.
However, Kassell acknowledged that the clinical evidence for focused ultrasound across a broad range of diseases remains limited despite its potential.
Biomedicine Sector Impact
The potential for non-invasive treatments using focused ultrasound could transform segments of the biomedicine industry. This development may attract increased investment into research and development for such innovative technologies. Companies that are developing or licensing focused ultrasound platforms could experience higher valuations.
Addressing difficult-to-treat cancers and neurodegenerative diseases with new methods responds to a substantial unmet medical need globally.
Asia's Role in Medical Innovation
Asian research hubs, particularly those in Hong Kong, are playing a key role in these global clinical trial efforts. This involvement positions regional biotech and healthcare firms to benefit from future advancements in medical technology. Other burgeoning biotech sectors in Asia, such as those in Singapore and South Korea, could also attract significant investment.
The adoption of new medical technologies across Asia could drive demand for specialised equipment and training by 2029, potentially fostering new partnerships and intellectual property licensing deals within the region.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.